Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M])

American Journal of Cardiology

Volumn 92, Issue 7, 2003, Pages 789-793

  Hirayama, Atsushi ^a   Kodama, Kazuhisa ^b   Yui, Yoshiki ^b   Nonogi, Hiroshi ^b   Sumiyoshi, Tetsuya ^b   Origasa, Hideki ^b   Hosoda, Saichi ^b   Kawai, Chuichi ^b  

^a OSAKA POLICE HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; TRAPIDIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; FEMALE; FOLLOW UP; HEADACHE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH DISEASE; TREATMENT OUTCOME; VERTIGO;

EID: 0141682427     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00884-1     Document Type: Article

References (9)

1. Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S., McGoon D.C., Murphy M.L., Roe B.B. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 51:1975;5-40.
2. Dodge H., Sandler H., Baxley W., Hawley R. Usefulness and limitation of radiographic methods for determining left ventricular volume. Am J Cardiol. 18:1966;10-24.
3. Saito M., Fukami K., Hiramori K., Haze K., Sumiyoshi T., Kasagi H., Horibe H. Long-term prognosis of patients with acute myocardial infarction is mortality and morbidity as low as the incidence of ischemic heart disease in Japan . Am Heart J. 113:1987;891-897.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
5. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 330:1994;1287-1294.
6. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89-95.
7. Kato Y., Tsuda T., Hosaka Y., Takahashi T., Shirakawa K., Furusako S., Mizuguchi K., Mochizuki H. Effect of trapidil on effector functions of monocytes related to atherosclerotic plaque. Eur J Pharmacol. 44:2000;307-316.
8. Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, Ishikawa K, Masuda Y, Yamaguchi T, Motomiya T, Tamura Y, on behalf of the Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol 1999;83:1308-1313.
9. Maresta A., Balducelli M., Cantini L., Casari A., Chioin R., Fabbri M., Fontanelli A., Preti P.A.M., Repetto S., De Servi S., Varani E. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation. 90:1994;2710-2715.